Staging of intestinal‐ and diffuse‐type gastric cancers with the OLGA and OLGIM staging systems
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Summary: Background: Operative link on gastritis assessment (OLGA) and Operative link on gastric intestinal metaplasia assessment (OLGIM) staging systems have been proposed for gastric cancer (GC) risk estimation. Aim: To validate the OLGA and OLGIM staging systems in a region with high risk of GC. Methods: This retrospective study included 474 GC patients and age‐ and sex‐matched health screening control persons in a cancer centre hospital. We classified gastritis patterns according to the OLGA and OLGIM systems using the histological database that a pathologist prospectively evaluated using the updated Sydney system.GC risk according to the OLGA and OLGIM stages was evaluated using logistic regression analysis. Results: More GC patients had OLGA stages III–IV(46.2%) than controls (26.6%,P < 0.001), particularly among patients with intestinal‐type GCs (62.2%) compared with diffuse‐type GCs (30.9%).OLGA stages III and IV were significantly associated with increased risk of GC[odds ratios (OR s), 2.09;P = 0.008 and 2.04;P = 0.014 respectively] in multivariate analysis. The association was more significant for intestinal‐type (OR s, 4.76;P = 0.001 and 4.19;P = 0.002 respectively), but not diffuse‐type GC.OLGIM stages from I to IV were significantly associated with increased risk of both intestinal‐type (OR s, 3.64, 5.15, 7.89 and 13.20 respectively) and diffuse‐type GC(OR s, 1.84, 2.59, 5.08 and 6.32 respectively) with a significantly increasing trend. Conclusion: As high OLGA and OLGIM stages are independent risk factors for gastric cancer, the staging systems may be useful for risk assessment in high‐risk regions, especially for intestinal‐type gastric cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Classification and Grading of Gastritis: The Updated Sydney System
Dixon, M. F., Genta, R. M., Yardley, J. H., & Correa, P. (1996) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199610000-00001 · Cited by 5,185
Capelle, L. G., de Vries, A. C., Haringsma, J., Ter Borg, F., de Vries, R. A., Bruno, M. J., van Dekken, H., Meijer, J., van Grieken, N. C. T., & Kuipers, E. J. (2010) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2009.12.029 · Cited by 608 · cited 3×
“assessed the gastritis stage based on the OLGIM staging system.(8) The antrum lesser curvature was considered non-oxyntic gastric mucosa (antrum score), and corpus lesser curvature was considered oxyntic gastric mucosa”
BackgroundMethodInfluentialGastritis staging in clinical practice: the OLGA staging system
Rugge, M., Meggio, A., Pennelli, G., Piscioli, F., Giacomelli, L., De Pretis, G., & Graham, D. Y. (2007) · Gut · doi:10.1136/gut.2006.106666 · Cited by 510
Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading
Rugge, M., Correa, P., Dixon, M. F., Fiocca, R., Hattori, T., Lechago, J., Leandro, G., Price, A. B., Sipponen, P., Solcia, E., et al. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01301.x · Cited by 372
Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study
RUGGE, M., DE BONI, M., PENNELLI, G., DE BONA, M., GIACOMELLI, L., FASSAN, M., BASSO, D., PLEBANI, M., & GRAHAM, D. Y. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04277.x · Cited by 280
Cited by
Pimentel-Nunes, P., Libânio, D., Marcos-Pinto, R., Areia, M., Leja, M., Esposito, G., Garrido, M., Kikuste, I., Megraud, F., Matysiak-Budnik, T., et al. (2019) · Endoscopy · doi:10.1055/a-0859-1883 · Cited by 993
Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer
Choi, I. J., Kook, M.-C., Kim, Y.-I., Cho, S.-J., Lee, J. Y., Kim, C. G., Park, B., & Nam, B.-H. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1708423 · Cited by 673
Self-citationDiagnosis and Management of High Risk Group for Gastric Cancer
Yoon, H., & Kim, N. (2015) · Gut and Liver · doi:10.5009/gnl14118 · Cited by 262
Lahner, E., Zagari, R. M., Zullo, A., Di Sabatino, A., Meggio, A., Cesaro, P., Lenti, M. V., Annibale, B., & Corazza, G. R. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.09.016 · Cited by 187
Yue, H., Shan, L., & Bin, L. (2018) · Gastric Cancer · doi:10.1007/s10120-018-0812-3 · Cited by 183
Metadata
- Authors
- Cho, S. ‐., Choi, I. J., Kook, M. ‐., Nam, B. ‐., Kim, C. G., Lee, J. Y., Ryu, K. W., & Kim, Y. ‐.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2013-10-06
- Volume
- 38
- Issue
- 10
- Pages
- 1292-1302
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W1973023131
- Cited by
- 91
- References
- 5
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.